Women & HIV Back grey_arrow_rt.gif
AIDS is the leading cause of death among African American and Hispanic women ages 25-44 in the US. African American and Hispanic women accounted for 76% of new AIDS cases among women reported in 1996 in the US. Women are one of the fastest growing groups of new AIDS cases, accounting for 20% of newly reported cases in the US and 42% of new cases worldwide. In clinical research on potential treatments, only 12% of research participants are female. Women are 33% more likely to die than men because treatment begins so much later, if at all.
  1. HCV & Women - several key reports - (03/10/15)
  2. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14)
  3. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study - (03/15/13)
  4. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13)
  5. The Association of Race, Sociodemographic, and Behavioral Characteristics With Response to Highly Active Antiretroviral Therapy in Women: 'depression, black/latino women, HAART discontinuation, higher death rates, drug use all related' - (04/03/12)
  6. Women & HIV: Medical Care for Menopausal and Older Women With HIV Infection - (03/29/12)
  7. Women & HIV: Testosterone & HIV+ Women - adverse events - (03/29/12)
  8. Women & HIV: Gender Gap in CVD: The Epidemiology of Cardiovascular Disease in Postmenopausal Women-see article below - (03/29/12)
  9. Women & HIV: Sex Differences in the Pharmacologic Effects of Antiretroviral Drugs: Potential Roles of Drug Transporters and Phase 1 and 2 Metabolizing Enzymes - (03/29/12)
  10. Women & HIV: Women & HIV: Black Women in USA; trauma; childhood sex abuse; heart disease in HIV+ women - (03/29/12)
  11. Women & HIV: Heart Disease & Women HIV+, inflammation: Obesity and Dyslipidemia in Behaviorally HIV-Infected Young Women: Adolescent Trials Network Study 021 - (03/29/12)
  12. Women & HIV: Gender differences in the treatment of HIV infection - review - (03/29/12)
  13. 2nd Intrntnl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/11/12)
  14. 2nd Intrntnl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
  15. 2nd Intrntnl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
  16. 2nd Intrntnl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
  17. 2nd Intrntnl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
  18. 2nd Intrntnl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
  19. 2nd Intrntnl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
  20. 2nd Intrntnl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
  21. 2nd Intrntnl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
  22. 2nd Intrntnl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
  23. 2nd Intrntnl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
  24. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
  25. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
  26. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
  27. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
  28. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
  29. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
  30. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
  31. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
  32. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
  33. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
  34. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
  35. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
  36. 1st Intrnl Wrkshp HIV & Women: Microbicide Disclosure to Partners Did & Results of CAPRISA 004 - written by Mark Mascolini - (01/11/11)
  37. 1st Intrnl Wrkshp HIV & Women: Striking Regional Antiretroviral Response Differences Found in Canadian Women - written by Mark Mascolini - (01/11/11)
  38. 1st Intrnl Wrkshp HIV & Women: Violence Linked to Substance Use and Mental Health in BC Women With HIV - written by Mark Mascolini - (01/11/11)
  39. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - written by Mark Mascolini - (01/11/11)
  40. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - written by Mark Mascolini - (01/11/11)
  41. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - written by Mark Mascolini - (01/11/11)
  42. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
  43. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
  44. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
  45. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
  46. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
  47. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
  48. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
  49. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
  50. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
  51. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
  52. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
  53. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/09)
  54. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
  55. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
  56. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
  57. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
  58. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (08/03/09)
  59. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
  60. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
  61. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
  62. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
  63. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
  64. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
  65. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
  66. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
  67. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
  68. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
  69. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
  70. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
  71. Routine HIV testing recommended for women - (04/08/09)
  72. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
  73. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
  74. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
  75. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
  76. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
  77. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
  78. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
  79. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women: "Our findings show that the prevalence of AIN among HIV-infected women is high and significantly increased above a comparison group of HIV-uninfected women." - (12/15/08)
  80. HIV CRISIS: AIDS is the leading cause of death for African-American women ages 25-34 today - (10/31/08)
  81. HIV Doctors May Treat All Infected, Adding Thousands: When To Start HAART Debate - (10/31/08)
  82. ICAAC: Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08)
  83. ICAAC: Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08)
  84. ICAAC: Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)
  85. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women - (10/08/08)
  86. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
  87. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors - (10/08/08)
  88. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
  89. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle - (09/23/08)
  90. Breast milk purged of HIV virus by Nipple Shield+Chemical - (09/22/08)
  91. HAART, Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire - (09/18/08)
  92. Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission - (09/8/08)
  93. IAS: Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) -
  94. IAS: Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) -
  95. IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) -
  96. IAS: HIV Crosses the Gender Divide - (08/19/08) -
  97. Enhancement of HIV Infection by Cellulose Sulfate - (07/31/08)
  98. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (07/31/08)
  99. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort - (07/29/08)
  100. Extended nevirapine prophylaxis to prevent HIV transmission - (07/29/08)
  101. Viagra for Women with Antidepressant-Associated Sex Dysfunction - (07/25/08)
  102. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
  103. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
  104. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
  105. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
  106. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
  107. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
  109. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
  110. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine (09/26/07)
  111. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
  112. Diaphragm and lubricant gel + Condom for prevention of HIV acquisition in southern African women: a randomised controlled trial - (07/19/07)
  113. U.S. NIH Funded Trial of VivaGel in Sexually Active Young Women Commences - (07/17/07)
  114. "He Won't Use Condoms": HIV-Infected Women's Struggles in Primary Relationships With Serodiscordant Partners - (07/02/07)
  115. Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV-Infected Women - (06/20/07)
  116. Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens in WIHS (Women) - (05/22/07)
  117. Hysterectomy Among Women With HIV: Indications and Incidence - (05/22/07)
  118. Resistance to Antiretroviral Drugs: A Threat to the Prevention and Treatment of Pediatric HIV Infection EDITORIAL COMMENTARY - (05/03/07)
  119. Early Archiving and Predominance of NNRTI-Resistant HIV-1 among Recently Infected Infants Born in the United States - (05/03/07)
  120. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children - (04/29/07)
  121. Assessment of Birth Defects According to Maternal Therapy Among Infants in the Women and Infants Transmission Study (WITS) - (04/03/07)
  122. Use of ART in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis - (04/03/07)
  123. Dose-Ranging Phase 1 Study of TMC120, a Promising Vaginal Microbicide, in HIV-Negative and HIV-Positive Female Volunteers - (02/23/07)
  124. Safety of nevirapine in pregnancy - (01/19/07)
  125. Extra-Hepatic HCV in HIV+ Women: Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Antibody HCV-Positive/HIV-Infected Women - (01/03/07)
  126. Cervical Shedding of HIV-1 RNA Among Women With Low Levels of Viremia While Receiving HAART - (01/04/07)
  127. Discontinuation of ART Postpartum: No Evidence for Altered Viral Set Point [Letters to the Editor] - (01/04/07)
  128. Human Papilloma Virus (HPV) Infection of the Anus Is More Prevalent and Diverse than Cervical HPV Infection among HIV-Infected Women in the SUN Study - (12/08/06)
  129. Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy - (12/08/06)
  130. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States / Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy - (10/20/06)
  131. ICAAC: Tenofovir and Lopinavir Levels in Pregnant Women and Infants - Written for NATAP by Mark Mascolini - (10/16/06)
  132. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities - (09/12/06)
  133. Longitudinal Analysis of Bone Density in HIV-Infected Women - (09/06/06)
  134. The mother-to-child HIV transmission epidemic in Europe (Ukraine & Eastern Europe): evolving in the East and established in the West - (07/17/06)
  135. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women - (05/17/06)
  136. HAART & Fetal death/Pre-eclampsia - (04/24/06)
  137. Antioxidant supplementation in pre-eclampsia: Commentary - (04/24/06)
  138. Heart Disease Prevention in Women (men too) - (04/24/06)
  139. Errors in Celia Farber's March 2006 article in Harper's Magazine - (03/15/06)
  140. HCV Mother-to-child transmission: HAART May Reduce HCV MTC; C-Section Did Not Reduce MTC - (03/15/06)
  141. HIV-Positive Latina Immigrants in California - (02/28/06)
  142. CROI: Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV (02/27/06)
  143. Tenofovir may be safe as vaginal HIV microbicide - (02/24/06)
  144. CROI: Tenofovir Achieves High Levels in the Genital tract of Men & Women and Reduces HIV RNA in Genital Tract of Men & Women (02/13/06)
  145. WISE Study of Women and Heart Disease Yields Important Findings on Frequently Undiagnosed Coronary Syndrome - (01/31/06)
  146. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
  147. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
  148. Experimental vaginal gel inhibits HIV and HSV - (01/25/06)
  149. PRO 2000 Gel Inhibits HIV and Herpes Simplex Virus Infection Following Vaginal Application: A Double-Blind Placebo-Controlled Trial - (01/05/06)
  150. Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier Protection - (01/05/06)
  151. HCV Transmission Risks from Mother-To-Child up to 6.2% - (11/09/05)
  152. Vaginal Microbicide Gel Phase III Study Enrolled - (10/28/05)
  153. Vaginal Gel Trials Start in South Africa - (10/28/05)
  154. Microbicide Study in Women Begins - (10/25/05)
  155. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women - (10/05/05)
  156. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
  157. Protease Inhibitor Use in 233 Pregnancies - (09/14/05)
  158. Therapy-associated severe hyperlactatemia rare in HIV patients - (09/02/05)
  159. 2 Articles on Pregnancy in HIV: HAART & Congential Abnormalities; Mitochondrial Toxicity in Uninfected Newborns - (09/02/05)
  160. IAS: Atazanavir Use in Pregnancy (08/05/05)
  161. Low-dose oral contraceptives increase cardiovascular disease risk - (07/13/05)
  162. High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women - (07/20/05)
  163. Safety, Acceptability, and Potential Efficacy of a Topical Penile Microbicide Wipe - (07/08/05)
  164. HIV-Positive U.S. Women More Concentrated in South, Among Minorities, CDC Says at HIV Prevention Conference in Atlanta - (06/16/05)
  165. Early antiretroviral therapy decreases progression of perinatal HIV - (05/13/05)
  166. EASL: HIV & High HCV Viral load Increased HCV Perinatal Transmission (05/05/05)
  167. Body Changes in Women Associated with Heart Disease Risk: "Increased Cardiovascular Disease Risk Indices in HIV-Infected Women" - (05/04/05)
  168. HIV load and CD4+ cell count affect HPV detection in HIV-infected women - (04/22/05)
  169. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy - (04/12/05)
  170. 25% of Women in WIHS Stop HAART for at least 6 Months - (04/01/05)
  171. Gender Affect in HIV & HAART - (04/01/05)
  172. "Women At Risk: The Health of Women in New York City" Report Released - (04/01/05)
  173. CROI: Prevention of mother-to-child transmission and nevirapine resistance - Reported for NATAP by David Margolis, MD - (03/09/04)
  174. Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (02/07/05)
  175. Fat Distribution in HIV-Infected Women in the United States: DEXA Substudy in the Women's Interagency HIV Study - (12/21/04)
  176. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with HAART in Europe - (12/15/04)
  177. Protease Inhibitor and NNRTI Concentrations in the Genital Tract of HIV+ Women - (12/06/04)
  178. HIV-Associated Anal Cancer: Has Highly Active Antiretroviral Therapy Reduced the Incidence or Improved the Outcome? - (12/06/04)
  179. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/04)
  180. HAART Resolves Life-Threatening Anemia in Women - (10/05/04)
  181. Women & HIV-CDC Updates HIV/AIDS Surveillance Among Women in US - (09/27/04)
  182. Glaxo AIDS Drugs to Be Tested In Topical Form, as Microbicide - (09/24/04)
  183. Depression & No HAART Increases Risk for AIDS-Death Among HIV+ Women in WIHS - (09/21/04)
  184. Nelfinavir Plasma Concentrations Are Low during Pregnancy - (09/07/04)
  185. Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (08/30/04)
  186. Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, avascular necrosis, mitochondrial toxicity - (08/20/04)
  188. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe - (07/01/04)
  189. Cancer Risk Among Participants in the Women's Interagency HIV Study - (06/30/04)
  190. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery - (06/28/04)
  191. Persistance of HPV in HIV+ Adolescent Girls - (06/28/04)
  192. Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 - (06/22/04)
  193. Contraceptive Use in HIV-Positive Women - (06/07/04)
  194. NRTIs and Intracellular Activity and Toxicities for Women, Advanced HIV & Hepatitis - (05/17/04)
  195. Smoking Increases Risk for Cervical Cancer in HIV+ - (05/10/04)
  196. Famcyclovir for Herpes Simplex Virus Shedding in Women - (05/10/04)
  197. Gender, Pregnancy, and PKs - (05/10/04)
  198. Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update - (05/04/04)
  199. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir - (05/03/04)
  200. Women with HIV can benefit from testosterone treatment - (04/27/04)
  201. Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus Associated Genital Lesions in HIV-Positive Women - (04/05/04)
  202. HIV in Semen, Effect of HAART, Sexual Transmission of HIV, & Relevance in Getting Pregnant - (03/31/04)
  203. Reduced bone density in HIV-infected women - (03/10/04)
  204. Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (02/23/04)
  205. CROI: HIV Microbocides at the 11th Retrovirus Conference - (02/23/04)
  206. The effect of hormonal contraception on genital tract shedding of HIV-1 - (02/06/04)
  207. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program in WIHS Study - (01/26/04)
  208. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes - (01/05/04)
  209. AZT Monotherapy To Prevent Perinatal Transmission - (01/05/04)
  210. Increased Risk for Fat Loss in HIV+ Women Observed in WIHS Study - (12/08/03)
  211. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
  212. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
  213. EACS - HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
  214. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals - (10/8/03)
  215. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women - (9/30/03)
  216. Microbicides: STD Protection With or Without Contraception - (8/18/03)
  217. Background Information Microbicide Drug Candidates Including Cyanovirin-N To Prevent Anal & Vaginal HIV Transmission - (8/18/03)
  218. FDA Hearing on Microbicides to Prevent HIV Transmission to Women: trial considerations - (8/18/03)
  219. Sperm washing in the UK: evidence of safety and efficacy - (4/30/03)
  220. High Rates of Viral Infections & HCV and For Risk Factors Among HIV-Infected and High-Risk HIV-Uninfected Women - (4/21/03)
  221. Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV-Infected Women - (4/2/03)
  222. Prevalence of Genotypic Drug Resistance Among a Cohort of HIV-Infected Newborns: suggesting resistance testing in newborns - (4/2/03)
  223. HCV in Semen - (3/26/03)
  224. Night Before or After Pill To Prevent HIV Transmission - (3/17/03)
  225. Retro - Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (3/10/03)
  226. Resistance Testing Recommended For Pregnant Women: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Observed Among Antiretroviral-Naive HIV-Positive Pregnant Women - (3/6/03)
  227. Perinatal Hepatitis C Virus Transmission: Role of Human Immunodeficiency Virus Infection and Injection Drug Use - Gregory L. Armstrong, Joseph F. Perz, and Miriam J. Alter Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia - (2/28/03)
  228. Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)Specific T Cell Responses in Primary HIV Infection - (2/26/03)
  229. Tale of Two Epidemics: The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus - (2/26/03)
  230. Retroconference Update: HIV and Women Written for NATAP by Judith Aberg, MD, Washington University, St Louis, MO, ACTG - (2/24/03)
  231. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women - (12/02/02)
  232. Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)
  233. Viral load in HCV RNA-positive pregnant women - (9/18/02)
  234. Hep C & Pregnancy: risks for transmission - (9/18/02)
  235. Does Patient Gender Affect Human Immunodeficiency Virus Levels? - (9/13/02)
  236. Women With Impaired Glucose Tolerance During Pregnancy Have Significantly Poor Pregnancy Outcomes - (8/27/02)
  237. Depression & Anxiety Can Occur in Diabetics and Their Partners, Particularly Women - (8/27/02)
  238. Sperm Washing for Pregnancy in HIV - (8/27/02)
  239. Barcelona - Anal Sex Increases Risk For Heterosexual HIV Transmission - (7/17/02)
  240. Kaletra in Women - (7/12/02)
  241. Recurrence rate of cervical dysplasia high in HIV-positive women - 06/12/02
  242. Women and HCV - (06/03/02)
  244. Women with HIV: More conference time Written for NATAP by Judith Aberg, MD, Washington University, Director of HIV Clinic, St Louis - (03/19/02)
  245. Maternal - Fetal Transmission at Retrovirus Written by Danielle Milano, MD, Boriken Family Health Services, New York - (03/18/02)
  246. HIV and Women at Retrovirus Written for NATAP by Danielle Milano, MD, Boriken Family Health Services, NYC - (03/18/02)
  247. Kidney failure in Women with HIV - (02/21/02)
  248. HIV Therapy for Pregnant Women - (02/20/02)
  249. AIDS Experts Cite New Opportunities: women/minorities/pregnancy by Vanessa Palo- The Associated Press - (02/11/02)
  250. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women - (12/27/01)
  252. Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy - (11/01/01)
  253. Screening for Anal and Cervical Dysplasia in HIV-Infected Patients PDF - (10/11/2001)
  254. Discontinuation of primary Pneumocystis carinii prophylaxis after reconstitution of CD4 cell counts in HIV-infected children - (9/14/01)
  255. Preventing disease by protecting the cervix: the unexplored promise of
    internal vaginal barrier devices
     (with PDF attached) - (9/20/01)
  256. Mother-to-Infant Transmission of Hepatitis C Virus - with full version in PDF format - (9/14/01)
  257. Gynecologic Problems for Women with HIV - in PDF format only from A Guide to the Clinical Care of Women with HIV - (9/10/01)
  258. Italian Study Finds HIV Delays Sexual Maturation in Boys & Girls Infected by their Mothers - (8/27/01)
  259. Gender Differences in Morphologic Alterations (Body Changes or Lipodystrophy) - (8/27/01)
  260. Mother-to-Child Transmission - (8/27/01)
  261. Role of HAART in Development of Hypertension Among HIV-Infected Women - (8/27/01)
  262. Access to Care for Women - (8/27/01)
  263. HPV Infection in Women and Men - Written for NATAP by Danielle Milano, MD - (8/2/01)
  264. HCV & Pregnancy, risk factors for transmission: breastfeeding, c-section, use of forceps in delivery - (8/1/01)
  265. Prevalence and Risk Factors for Anal Squamous Intraepithelial Lesions in Women - (6/15/2001)
  266. Immune Suppression and the Risk for Cervical Dysplasia - (5/15/2001)
  267. Women in HIV: - Highlights from the 8th Annual Retrovirus Conference (in simpler easier-to-read version)
    Written for NATAP by Kathleen Squires, MD, edited by Jules Levin, NATAP (3/07/2001)
  268. HIV Infection in Women - Reported for NATAP by Kathleen Squires, MD - (3/5/2001)
  269. Selected Highlights on HIV Transmission, Women & Children: HAART reduces perinatal transmission - (2/19/2001)
  270. Transmission From Mother to Newborn is Preventable if Viral Load is <1000 copies/ml at Delivery (1%) - (2/19/2001)
  271. HAART has a beneficial effect for women with HIV with Cervical Intraepithelial Neoplasia (CIN) - (2/19/2001)
  272. Women and Children Get HIV Also! - by Judith A. Aberg, M.D
  273. Women and Clinical Trials
  274. The HIV-Positive Woman: Are You Getting Good Medical Care? - by Debra Johnson, NP, PA-C and Kathleen E. Squires, MD - (2/16/2001)